CM Life Sciences III Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CM Life Sciences III Inc. (CMLTU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the life sciences sector; its search emphasizes fragmented areas including life sciences tools for research and development workflows, synthetic biology for engineering biological systems across human health and industrial applications, diagnostics such as molecular diagnostics with channel and content synergies, and ecosystem services supporting drug discovery, development, and manufacturing. Sponsored by affiliates of Casdin Capital LLC and Corvex Management LP, the company offers no current products or operational services beyond its SPAC structure, which provides redeemable units comprising one share of Class A common stock and one-fifth of a redeemable warrant exercisable at $11.50 per share. Founded in 2021 and headquartered at c/o Corvex Management LP in New York, New York, CM Life Sciences III conducts global operations with a focus on life sciences innovation, leveraging the proprietary deal flow, network of scientists, entrepreneurs, research institutions, and venture partners from Casdin Capital's over 100 private investments; its board includes CEO Eli Casdin, Chairman Keith Meister, and directors with expertise from companies like Pacific Biosciences, WAVE Life Sciences, and Adaptive Biotechnologies. The company completed its initial public offering in April 2021, raising $552 million through 55.2 million units at $10 each, with trading on Nasdaq under CMLTU. In August 2021, it announced a definitive business combination with EQRx Inc., a pharmaceutical developer aiming for lower-cost medicines, valued at a $3.65 billion pre-money enterprise value with up to $1.8 billion in proceeds including PIPE financing led by SoftBank; the merger closed in December 2021, with the combined entity debuting publicly as EQRx on Nasdaq, though subsequent developments including EQRx's 2023 acquisition by Sema4 Holdings Corp. (leading to GeneDx shares) and related stockholder litigation over redemptions and disclosures resulted in a $21 million settlement in 2024, reflecting no further de-SPAC activity for the original SPAC structure as of late 2025.
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
CM Life Sciences III Inc. Announces Separate Trading of Its Shares of Class A Common Stock and Warrants, on or About May 28, 2021
Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering